Keytruda (Pembrolizumab)

Pembrolizumab is a monoclonal antibody that binds to the PD‑1 receptor on T‑cells, blocking its interaction with PD‑L1 and PD‑L2 on tumor cells. This interruption lifts the inhibitory signal, reactivating T‑cells to recognize and attack cancer cells, thereby enhancing the body’s immune response against the tumor.

The dose of Keytruda is individualized by the prescribing physician based on the specific indication, patient’s body weight or surface area, disease stage, and clinical response. Dosing regimens are outlined in the product labeling, and the healthcare provider decides the appropriate schedule for each patient.

Safety data for pembrolizumab in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended while receiving treatment, and patients should discuss alternatives with their clinician.

To order Keytruda, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details (if applicable) and the necessary import documentation.

Keytruda belongs to the same class of PD‑1 checkpoint inhibitors as drugs like nivolumab and cemiplimab. While all share the same mechanism of blocking PD‑1, differences exist in approved indications, dosing schedules, and clinical trial outcomes. Choice of therapy depends on the specific cancer type, regulatory approvals, and physician judgment.

Keytruda must be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). It should be kept in its original carton, protected from light, and must not be frozen or shaken. Once prepared for infusion, it should be used within the time frame specified in the product labeling.

Keytruda is supplied as a sterile powder for solution for infusion. The powder is reconstituted with the appropriate diluent and administered intravenously over a period of 30 minutes, typically in an outpatient infusion center. The infusion schedule (e.g., every 3 weeks or every 6 weeks) is determined by the treating physician.

Serious risks include immune‑mediated adverse events such as pneumonitis, colitis, hepatitis, endocrinopathies (e.g., thyroiditis, adrenal insufficiency), severe skin reactions, and life‑threatening infusion reactions. Patients should be monitored closely for new or worsening symptoms, and any grade 3 or higher toxicity generally requires treatment interruption or discontinuation.

Keytruda is contraindicated in patients with known hypersensitivity to pembrolizumab or any of its excipients. It should be used with caution in individuals with active autoimmune diseases, organ transplants, or those receiving live vaccines. The decision to treat should be individualized by the healthcare provider based on the patient’s overall health status.